A. OVERVIEW The Administrative Core will coordinate and integrate facilifies, faculty, resources, and projects. The objectives of the Administrative Core include the following: 1. Oversee optimal use of Partnership funds and personnel resources; 2. Coordinate and integrate the Center Cores and component activities;and 3. Provide leadership and administrative support to the Partnership components, projects, and investigators. As demonstrated in Figure 2, Dr. Vadgama will be the Administrative Core Director and will oversee administrative activities. The Administrative Core comprises two teams, the Execufive Management Team and the Program Leadership Team. The Executive Management Team will comprise the core director and the program manager and manage funds and resources. The Executive Management Team will work closely with and be guided by the NCI program director, the Internal Advisory and Program Steering Committees of the Planning and Evaluation Core, and institutional leadership. The Program Leadership Team, consisting of all investigators and core/program leaders, will meet quarterly to be updated and involved with other core/program activities. The leadership team will be collaborative only and will not be a decision-making committee. The Administrative Core will coordinate these meetings and all cross-program communication to make certain that all Partnership components are informed, united, and/or working collaboratively on a consistent basis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA143931-05
Application #
8540356
Study Section
Special Emphasis Panel (ZCA1-SRLB-D)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2013
Total Cost
$430,485
Indirect Cost
$168,690
Name
Charles R. Drew University of Medicine & Science
Department
Type
DUNS #
785877408
City
Los Angeles
State
CA
Country
United States
Zip Code
90059
Chung, Seyung S; Oliva, Bryant; Dwabe, Sami et al. (2016) Combination treatment with flavonoid morin and telomerase inhibitor MST‑312 reduces cancer stem cell traits by targeting STAT3 and telomerase. Int J Oncol 49:487-98
Wu, Yanyuan; Sarkissyan, Marianna; Vadgama, Jaydutt V (2016) Epithelial-Mesenchymal Transition and Breast Cancer. J Clin Med 5:
Maxwell, Annette E; Danao, Leda L; Cayetano, Reggie T et al. (2016) Implementation of an evidence-based intervention to promote colorectal cancer screening in community organizations: a cluster randomized trial. Transl Behav Med 6:295-305
Wang, Piwen; Henning, Susanne M; Magyar, Clara E et al. (2016) Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy. J Exp Clin Cancer Res 35:73
Sherzai, Dean; Sherzai, Ayesha; Lui, Keith et al. (2016) The Association Between Diabetes and Dementia Among Elderly Individuals: A Nationwide Inpatient Sample Analysis. J Geriatr Psychiatry Neurol 29:120-5
Wang, Piwen; Phan, Tien; Gordon, David et al. (2015) Arctigenin in combination with quercetin synergistically enhances the antiproliferative effect in prostate cancer cells. Mol Nutr Food Res 59:250-61
Wang, Piwen; Henning, Susanne M; Heber, David et al. (2015) Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. J Nutr Biochem 26:408-15
Li, Youqiang; Wu, Yanyuan; Abbatiello, Thomas C et al. (2015) Slug contributes to cancer progression by direct regulation of ERα signaling pathway. Int J Oncol 46:1461-72
Dawes, Aaron J; Hemmelgarn, Marian; Nguyen, David K et al. (2015) Are primary care providers prepared to care for survivors of breast cancer in the safety net? Cancer 121:1249-56
Maxwell, Annette E; Young, Sandra; Rabelo Vega, Roena et al. (2015) Building Capacity to Address Women's Health Issues in the Mixtec and Zapotec Community. Womens Health Issues 25:403-9

Showing the most recent 10 out of 68 publications